MDNA:CC News and Press, Medicenna Therapeutics Corp. From 06/26/25

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical conferences and a planned KOL event MDNA11 continues to exhib...

Alimentation Couche-Tard Inc. (ATD:CA) is expected to report $0.65 for Q4 2025 GoldMoney Inc. (XAU:CA) is expected to report for quarter end 2025-03-31 Sprott Physical Gold and Silver Trust (CEF:CA) is expected to report for quarter end 2025-03-31 AGF Management Limited Class B Non-Vo...

Medicenna Therapeutics Corp. (MDNA:CA) is expected to report $-0.07 for Q4 2025

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK ), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenvironment (TME) IL-13Rα2 is overexpre...

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA ® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with histor...

2025-04-23 12:12:05 ET Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies. According to Grandview Research , the global biotec...

TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune dise...

TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune dise...

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion c...

- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA ® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial response and five stable disea...